留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

云南汉族人群mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性

杨佳 李娅娴 王莹莹 肖琳 李传印 谭芳 马千里 刘舒媛

杨佳, 李娅娴, 王莹莹, 肖琳, 李传印, 谭芳, 马千里, 刘舒媛. 云南汉族人群mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性[J]. 昆明医科大学学报, 2021, 42(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20211037
引用本文: 杨佳, 李娅娴, 王莹莹, 肖琳, 李传印, 谭芳, 马千里, 刘舒媛. 云南汉族人群mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性[J]. 昆明医科大学学报, 2021, 42(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20211037
Jia YANG, Ya-xian LI, Ying-ying WANG, Lin XIAO, Chuan-yin LI, Fang TAN, Qian-li MA, Shu-yuan LIU. Association of the miR-149,miR-219 and miR-let-7 Polymorphisms with the Occurrence and Development of Non-small Cell Lung Cancer in a Chinese Han Population in Yunnan Province[J]. Journal of Kunming Medical University, 2021, 42(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20211037
Citation: Jia YANG, Ya-xian LI, Ying-ying WANG, Lin XIAO, Chuan-yin LI, Fang TAN, Qian-li MA, Shu-yuan LIU. Association of the miR-149,miR-219 and miR-let-7 Polymorphisms with the Occurrence and Development of Non-small Cell Lung Cancer in a Chinese Han Population in Yunnan Province[J]. Journal of Kunming Medical University, 2021, 42(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20211037

云南汉族人群mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性

doi: 10.12259/j.issn.2095-610X.S20211037
基金项目: 国家自然科学基金资助项目(81573206);云南省应用基础研究计划-昆明医科大学联合专项基金资助项目(2018FE001-219,202001AY070001081);北京协和医学院中央高校基本科研业务费资助项目(3332019111);云南省医学后备人才项目(H-2018014)
详细信息
    作者简介:

    杨佳(1985~),女,云南大理人,理学学士,主管技师,主要从事免疫遗传学研究

    通讯作者:

    刘舒媛,E-mail: liushuyuan@imbcams.com.cn

  • 中图分类号: R734.2

Association of the miR-149,miR-219 and miR-let-7 Polymorphisms with the Occurrence and Development of Non-small Cell Lung Cancer in a Chinese Han Population in Yunnan Province

  • 摘要:   目的  探讨mircoRNA基因多态性与云南汉族人群非小细胞肺癌发生发展的相关性。  方法  选取云南地区汉族人群非小细胞肺癌患者415例,健康对照460例,采用Taqman探针基因分型法对3个SNP位点rs2292832 T>C (pre-miR-149)、rs107822 C>T(pre-miR-219a-1),rs629367 C>A (pri-let-7a-1)进行基因分型并分析其等位基因、基因型在非小细胞肺癌患者(按病理分层为鳞癌、腺癌及其他类型肺癌;按临床分期分层为I+II期、III+IV期)及健康对照中的频率差异。  结果  rs2292832、rs107822、rs629367位点的等位基因、基因型频率在非小细胞肺癌组和对照组间的差异没有统计学意义,在分层分析及遗传模式分析中也无显著性差异。  结论  rs2292832、rs107822、rs629367可能与云南汉族人群非小细胞肺癌无相关性。
  • 表  1  3个miRNA的SNP位点在总肺癌病例组和对照组的等位基因和基因型频率[n(%)]

    Table  1.   Allele and genotype frequencies of three SNPs in miRNA between total lung cancer case group and control group [n(%)]

    SNPs等位基因/基因型对照组(n = 460)总肺癌病例(n = 415)POR(95%CI)
    rs2292832 T 589(64.0) 563(67.8) 0.093 0.84(0.69~1.03)
    C 331(36.0) 267(32.2)
    T/T 193(42.0) 197(47.5) 0.243
    T/C 203(44.1) 169(40.7)
    C/C 64(13.9) 49(11.8)
    rs107822 T 534(58.0) 475(57.2) 0.731 1.03(0.86~1.25)
    C 386(42.0) 355(42.8)
    T/T 162(35.2) 145(34.9) 0.877
    T/C 210(45.7) 185(44.6)
    C/C 88(19.1) 85(20.5)
    rs629367 A 709(77.1) 643(77.5) 0.840 1.02(0.82~1.28)
    C 211(22.9) 187(22.5)
    A/A 277(60.2) 254(61.2) 0.934
    A/C 155(0.337) 135(0.325)
    C/C 28(0.061) 26(0.063)
    下载: 导出CSV

    表  2  分层分析3个miRNA的SNP位点在肺癌病例和对照组中的等位基因和基因型频率差异[n(%)](1)

    Table  2.   The allele and genotype frequency of three SNPs in lung cancer group and control group by stritification analysis [n(%)] (1)

    SNPs等位基因/基因型对照组鳞癌病例腺癌病例Ⅰ+Ⅱ期病例Ⅲ+Ⅳ期病例
    n = 460)n = 150)n = 241)n = 134)n = 281)
    rs2292832 T 589(64.0) 203(67.7) 320(66.4) 181(67.5) 382(0.680)
    C 331(36.0) 97(32.3) 162(33.6) 87(32.5) 180(32.0)
    T/T 193(42.0) 70(46.7) 110(45.6) 64(47.8) 133(47.3)
    T/C 203(44.1) 63(42.0) 100(41.5) 53(39.6) 116(41.3)
    C/C 64(13.9) 17(11.3) 31(12.9) 17(12.7) 32(11.4)
    rs107822 T 534(58.0) 169(56.3) 274(56.8) 140(52.2) 335(59.6)
    C 386(42.0) 131(43.7) 208(43.2) 128(47.8) 227(40.4)
    T/T 162(35.2) 50(33.3) 86(35.7) 38(28.4) 107(38.1)
    T/C 210(45.7) 69(46.0) 102(42.3) 64(47.8) 121(43.1)
    C/C 88(19.1) 31(20.7) 53(22.0) 32(23.9) 53(18.9)
    rs629367 A 709(77.1) 232(77.3) 376(78.0) 213(79.5) 430(76.5)
    C 211(22.9) 68(22.7) 106(22.0) 55(20.5) 132(23.5)
    A/A 277(60.2) 92(61.3) 150(62.2) 83(61.9) 171(60.9)
    A/C 155(33.7) 48(32.0) 76(31.5) 47(35.1) 88(31.3)
    C/C 28(6.1) 10(6.7) 15(6.2) 4(3.0) 22(7.8)
    下载: 导出CSV

    表  2  分层分析3个miRNA的SNP位点在肺癌病例和对照组中的等位基因和基因型频率差异[n(%)] (2)

    Table  2.   The allele and genotype frequency of three SNPs in lung cancer group and control group by stritification analysis [n(%)] (2)

    鳞癌病例vs对照组腺癌病例vs对照组Ⅰ+Ⅱ期病例vs对照组Ⅲ+Ⅳ期病例vs对照组
    POR(95%CI)POR(95%CI)POR(95%CI)POR(95%CI)
    0.251 0.85(0.64~1.12) 0.378 0.90(0.71~1.14) 0.289 0.86(0.64~1.14) 0.121 0.84(0.67~1.05)
    0.531 0.644 0.490 0.311
    0.603 1.07(0.82~1.40) 0.667 1.05(0.84~1.31) 0.091 1.26(0.96~1.66) 0.553 0.94(0.76~1.16)
    0.923 1.02(0.74~1.39) 0.688 1.06(0.81~1.38) 0.404 1.15(0.83~1.61) 0.807 0.97(0.76~1.24)
    0.913 0.846 0.375 0.578
    下载: 导出CSV

    表  3  3个SNP位点在不同遗传模式下与肺癌的相关性[n(%)]

    Table  3.   Iheritance model analysis of the association between lung cancer andthese 3 SNPs [n(%)]

    SNPs遗传模式基因型对照组(n = 460)总肺癌病例组
    n = 415)
    OR (95% CI)PAICBIC
    rs2292832 共显性模式 T/T 193 (42.0) 197 (47.5) 1 0.243 1215.7 1239.6
    T/C 203 (44.1) 169 (40.7) 0.81 (0.61~1.08)
    C/C 64 (13.9) 49 (11.8) 0.75 (0.49~1.15)
    显性模式 T/T 193 (42) 197 (47.5) 1 0.101 1213.8 1232.9
    T/C-C/C 267 (58.0) 218 (52.5) 0.80 (0.61~1.04)
    隐性模式 T/T-T/C 396 (86.1) 366 (88.2) 1 0.354 1215.8 1234.9
    C/C 64 (13.9) 49 (11.8) 0.83 (0.56~1.24)
    超显性模式 T/T-C/C 257 (55.9) 246 (59.3) 1 0.309 1215.5 1234.6
    T/C 203 (44.1) 169 (40.7) 0.87 (0.66~1.13)
    逻辑加性模式 --- --- --- 0.85 (0.70~1.03) 0.100 1213.9 1233
    rs107822 共显性模式 T/T 162 (35.2) 145 (34.9) 1 0.877 1218.3 1242.2
    C/T 210 (45.6) 185 (44.6) 1.00 (0.74~1.35)
    C/C 88 (19.1) 85 (20.5) 1.09 (0.75~1.59)
    显性模式 T/T 162 (35.2) 145 (34.9) 1 0.932 1216.5 1235.6
    C/T-C/C 298 (64.8) 270 (65.1) 1.03 (0.78~1.36)
    隐性模式 T/T-C/T 372 (80.9) 330 (79.5) 1 0.671 1216.3 1235.4
    C/C 88 (19.1 85 (20.5) 1.09 (0.78~1.53)
    超显性模式 T/T-C/C 250 (54.4) 230 (55.4) 1 0.750 1216.5 1235.6
    C/T 210 (45.6) 185 (44.6) 0.97 (0.74~1.27)
    逻辑加性模式 --- --- --- 1.04 (0.87~1.25) 0.680 1216.4 1235.5
    rs629367 共显性模式 A/A 277 (60.2) 254 (61.2) 1 0.943 1218.5 1242.3
    A/C 155 (33.7) 135 (32.5) 0.96 (0.72~1.28)
    C/C 28 (6.1) 26 (6.3) 1.01 (0.58~1.77)
    显性模式 A/A 277 (60.2) 254 (61.2) 1 0.765 1216.5 1235.6
    A/C-C/C 183 (39.8) 161 (38.8) 0.97 (0.74~1.27)
    隐性模式 A/A-A/C 432 (93.9) 389 (93.7) 1 0.913 1216.6 1235.7
    C/C 28 (6.1) 26 (6.3) 1.02 (0.59~1.78)
    超显性模式 A/A-C/C 305 (66.3) 280 (67.5) 1 0.715 1216.5 1235.6
    A/C 155 (33.7) 135 (32.5) 0.96 (0.72~1.27)
    逻辑加性模式 --- --- --- 0.98 (0.79~1.22) 0.870 1216.5 1235.6
    下载: 导出CSV
  • [1] Sung H,Ferlay J,Siegel R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
    [2] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2019,(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005
    [3] Albright F,Teerlink C,Werner T L,et al. Significant evidence for a heritable contribution to cancer predisposition:a review of cancer familiality by site[J]. BMC Cancer,2012,12:138. doi: 10.1186/1471-2407-12-138
    [4] Saliminejad K,Khorram Khorshid H R,Soleymani Fard S,et al. An overview of microRNAs:Biology,functions,therapeutics,and analysis methods[J]. J Cell Physiol,2019,234(5):5451-5465. doi: 10.1002/jcp.27486
    [5] Liao J,Shen J,Leng Q,et al. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC)[J]. Thorac Cancer,2020,11(3):762-768. doi: 10.1111/1759-7714.13337
    [6] Ryan B M,Robles A I and Harris C C. Genetic variation in microRNA networks:the implications for cancer research[J]. Nat Rev Cancer,2010,10(6):389-402. doi: 10.1038/nrc2867
    [7] Lin J,Zandi R,Shao R,et al. A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling[J]. Sci Rep,2017,7(1):9029. doi: 10.1038/s41598-017-09604-4
    [8] Beasley M B,Brambilla E and Travis W D. The 2004 World Health Organization classification of lung tumors[J]. Semin Roentgenol,2005,40(2):90-97. doi: 10.1053/j.ro.2005.01.001
    [9] Groome P A,Bolejack V,Crowley J J,et al. The IASLC Lung Cancer Staging Project:validation of the proposals for revision of the T,N,and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J]. J Thorac Oncol,2007,2(8):694-705. doi: 10.1097/JTO.0b013e31812d05d5
    [10] Shi Y Y and He L. SHEsis,a powerful software platform for analyses of linkage disequilibrium,haplotype construction,and genetic association at polymorphism loci[J]. Cell Res,2005,15(2):97-98. doi: 10.1038/sj.cr.7290272
    [11] Solé X,Guinó E,Valls J,et al. SNPStats:a web tool for the analysis of association studies[J]. Bioinformatics,2006,22(15):1928-1929. doi: 10.1093/bioinformatics/btl268
    [12] Wu M,Wang G,Tian W,et al. MiRNA-based Therapeutics for Lung Cancer[J]. Curr Pharm Des,2018,23(39):5989-5996. doi: 10.2174/1381612823666170714151715
    [13] Mishra S,Yadav T and Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics[J]. Crit Rev Oncol Hematol,2016,98:12-23. doi: 10.1016/j.critrevonc.2015.10.003
    [14] Wang R J,Zheng Y H,Wang P,et al. Serum miR-125a-5p,miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer[J]. Int J Clin Exp Pathol,2015,8(1):765-771.
    [15] Li C,Zhang Y,Li Y,et al. The association of polymorphisms in miRNAs with nonsmall cell lung cancer in a Han Chinese population[J]. Cancer Manag Res,2018,10:697-704. doi: 10.2147/CMAR.S154040
    [16] Dikeakos P,Theodoropoulos G,Rizos S,et al. Association of the miR-146aC>G,miR-149T>C,and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population[J]. Mol Biol Rep,2014,41(2):1075-1080. doi: 10.1007/s11033-013-2953-0
    [17] Wei W J,Lu Z W,Li D S,et al. Association of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population[J]. Int J Mol Sci,2014,15(11):20968-20981. doi: 10.3390/ijms151120968
    [18] Tu H F,Liu C J,Chang C L,et al. The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma[J]. PLoS One,2012,7(12):e51606. doi: 10.1371/journal.pone.0051606
    [19] Zhang M,Jin M,Yu Y,et al. Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population[J]. Eur J Cancer Care (Engl),2012,21(2):274-280. doi: 10.1111/j.1365-2354.2011.01308.x
    [20] Lv M,Dong W,Li L,et al. Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population[J]. J Cancer Res Clin Oncol,2013,139(8):1405-1410. doi: 10.1007/s00432-013-1456-7
    [21] Stenholm L,Stoehlmacher-Williams J,Al-Batran S E,et al. Prognostic role of microRNA polymorphisms in advanced gastric cancer:a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)[J]. Ann Oncol,2013,24(10):2581-2588. doi: 10.1093/annonc/mdt330
    [22] Zheng C,Li X,Xia L,et al. Polymorphisms of pri-miR-219-1 are associated with the susceptibility and prognosis of non-small cell lung cancer in a Northeast Chinese population[J]. Oncotarget,2017,8(34):56533-56541. doi: 10.18632/oncotarget.17035
    [23] Song X,You W,Zhu J,et al. A Genetic Variant in miRNA-219-1 Is Associated with Risk of Esophageal Squamous Cell Carcinoma in Chinese Kazakhs[J]. Dis Markers,2015,54:1531.
    [24] Xu Q,Dong Q,He C,et al. A new polymorphism biomarker rs629367 associated with increased risk and poor survival of gastric cancer in chinese by up-regulated miRNA-let-7a expression[J]. PLoS One,2014,9(4):e95249. doi: 10.1371/journal.pone.0095249
  • [1] 洪超, 向旭东, 李盈甫, 曹杨, 陈雪雅, 李帅, 邢安灏, 林牧, 马千里.  ERK1/2信号通路基因3'UTR多态性与非小细胞肺癌的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240302
    [2] 牛志鑫, 汤丽华, 史磊, 洪超, 姚宇峰, 严志凌.  MAPK1NRAS基因多态性与云南汉族人群宫颈上皮内瘤变的相关性, 昆明医科大学学报.
    [3] 陈杭, 崔琦, 黄敏杉, 刘建军, 马岚青.  miRNA在非酒精性脂肪性肝病中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240101
    [4] 李春桃, 张雪梅, 苏琰迪, 张剑青.  过表达及敲减LncRNA RP11-521C20.3的非小细胞肺癌A549稳转细胞株的构建, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231016
    [5] 陆小华, 袁洪新.  BTLA、CTLA-4基因多态性与肝癌TACE联合靶向治疗疗效及预后相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230927
    [6] 董妍, 李雯雯, 崔文龙, 刘杰, 毕卫红.  云南省两县农村老年人慢性病与体力劳动强度相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230303
    [7] 梁燕, 王磊, 雷鸣, 陈本超, 孙萍, 李帅, 刘莉, 王倩蓉, 廖曼霖, 马千里.  KRAS基因多态性与云南汉族人群非小细胞肺癌的相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230210
    [8] 马燕粉, 胡健, 蔡德佩, 乔永峰, 王晓琴.  3137例体检人群血清GGT水平和血脂指标的相关性研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221001
    [9] 张天红, 杨红菊.  外泌体miRNA在肝细胞癌中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220221
    [10] 王应霞, 何琴, 王国芳, 张旋.  非小细胞肺癌中microRNA-21和EGFR的表达及意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210818
    [11] 崔朴梅, 陈太方, 陈超, 梁永梅, 徐悦.  云南某医院2016年至2019年抗菌药物使用与常见细菌耐药性的相关性分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211127
    [12] 陈本超, 李恒, 刘超, 王书廷, 李高峰.  G蛋白偶联受体激酶5与非小细胞肺癌的临床相关性, 昆明医科大学学报.
    [13] 马晓骉, 罗峰, 高永亮, 郝静超.  CIK细胞免疫疗法联合化疗治疗非小细胞肺癌的临床疗效, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201215
    [14] 王娟, 苏国苗, 潘国庆, 边莉, 杨哲, 曾定涛.  云南地区非小细胞肺癌EGFR、ALK和ROS1基因突变联合检测, 昆明医科大学学报.
    [15] 唐诗聪, 潘泓, 黄耀元, 周鑫, 王守峰, 左传田, 茅乃权.  人非小细胞肺癌裸鼠移植瘤模型的建立, 昆明医科大学学报.
    [16] 周喆焱.  E-cadherin对非小细胞肺癌的转移和靶向治疗的影响, 昆明医科大学学报.
    [17] 张红.  外周血红细胞和血红蛋白因素与高原地区高尿酸血症患者相关性分析, 昆明医科大学学报.
    [18] 赵金友.  云南省城市空巢老人孤独状况与生命质量相关性分析, 昆明医科大学学报.
    [19] 杨芳.  两种不同形式的TNF相关凋亡诱导配体对非小细胞肺癌作用的研究, 昆明医科大学学报.
    [20] 张兰凤.  易瑞沙治疗晚期非小细胞肺癌的临床观察, 昆明医科大学学报.
  • 加载中
计量
  • 文章访问数:  3920
  • HTML全文浏览量:  2155
  • PDF下载量:  16
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-08
  • 网络出版日期:  2021-10-29
  • 刊出日期:  2021-10-30

目录

    /

    返回文章
    返回